Financial Data and Key Metrics Changes - In Q4 2025, total net revenue was $34.1 million, including $26.4 million from MIPLYFFA sales, $400,000 from OLPRUVA, and $5.6 million from net reimbursements under the global EAP [22][23] - For the full year 2025, net revenue reached $106.5 million, with $87.4 million from MIPLYFFA sales, compared to a net loss of $105.5 million in 2024 [25] - Operating expenses for Q4 2025 were $23 million, a decrease of $1.5 million year-over-year, while R&D expenses decreased by $5.8 million to $2.6 million [22][24] Business Line Data and Key Metrics Changes - MIPLYFFA generated $87.4 million in revenue for the full year 2025, with a total of 161 enrollments since launch, including 52 in the first full year of commercialization [5][6][15] - The global expanded access program (EAP) had 113 patients enrolled by the end of 2025, with ongoing efforts to expand access beyond the U.S. [8][9] Market Data and Key Metrics Changes - In the U.S., the estimated prevalence of Niemann-Pick disease type C (NPC) is approximately 900 individuals, with 300-350 currently diagnosed [7][10] - In Europe, the estimated prevalence of NPC is around 1,100 individuals, with the current EAP supporting nearly 10% of this population [9] Company Strategy and Development Direction - The company aims to redefine therapies for rare diseases, focusing on patient-centricity and innovation [4] - A strategic move to Boston is intended to enhance collaboration and access to specialized talent within the biotech ecosystem [12] - The company is pursuing a patent term extension for MIPLYFFA, which could provide additional exclusivity [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MIPLYFFA, driven by strong clinical data and increased awareness among healthcare providers [15][16] - The company is optimistic about the continued identification of newly diagnosed patients and the overall market potential for MIPLYFFA [16][20] Other Important Information - The company has engaged the FDA regarding regulatory options to accelerate the development of celiprolol for vascular Ehlers-Danlos syndrome [12][70] - The company has a strong balance sheet with $238.9 million in cash and equivalents, allowing for independent operation and investment in growth opportunities [90] Q&A Session Summary Question: Can you provide details on the split of new diagnoses versus previously identified patients? - Management noted that there has been meaningful growth in newly diagnosed patients, attributed to clinical data strength and disease awareness campaigns [32][33] Question: What is the expected timeline for diagnosis confirmation? - The average time for test results is estimated to be about three weeks, facilitating quicker clinical decision-making [41] Question: Can you discuss persistency rates for patients on therapy? - Management indicated that it is too early to provide meaningful data on persistency but noted encouraging refill rates [46][47] Question: How is the initial experience with the Uniphar collaboration? - The company is pleased with the collaboration and expects continued growth in patient access through this partnership [48][49] Question: What is the total addressable market for diagnosed NPC patients? - Management believes they have engaged approximately 40%-50% of the diagnosed patients currently enrolled to receive MIPLYFFA [80]

Financial Data and Key Metrics Changes - Coherus Oncology reported a net revenue of $40.8 million for the full year 2025, representing a 113% increase from $19.1 million in 2024 [35] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025 [4][41] - SG&A expenses decreased to $23.6 million in Q4 2025 from $29.6 million in Q4 2024, marking the fourth consecutive quarter of flat or declining expenses [44] - R&D expenses increased to $31 million in Q4 2025 compared to $20.8 million in Q4 2024, reflecting ongoing investments in the pipeline [44] Business Line Data and Key Metrics Changes - LOQTORZI, the company's first innovative oncology product, saw its sales more than double in 2025 compared to 2024 [6][49] - For Q4 2025, LOQTORZI net revenue was $12.4 million, an 11% growth over Q3 2025, driven by a 15.5% increase in demand [35] - The company anticipates achieving peak market share of approximately 70% in the nasopharyngeal carcinoma (NPC) market by 2028, equating to $175 million in annualized revenues [7][40] Market Data and Key Metrics Changes - The NCCN guidelines for NPC were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which stimulated growth in 2025 [36] - The addressable market for LOQTORZI is estimated at $250 million, with significant opportunities remaining, particularly in the community segment [35][36] Company Strategy and Development Direction - Coherus has transitioned to focus on innovative oncology, particularly in overcoming immune resistance in cancer, following the acquisition of Surface Oncology [4] - The company aims to leverage LOQTORZI as a revenue generator while advancing its pipeline, including tagmokitug and Casdozokitug, which are positioned for broad clinical utility [6][10] - Strategic partnerships, such as the collaboration with Johnson & Johnson, are seen as key to expanding market reach and enhancing the value of the pipeline [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth trajectory, supported by strong clinical data showing significant survival benefits over chemotherapy alone [37] - The company is well-funded through 2026 and into 2027, allowing for continued investment in its promising pipeline and commercial efforts [9][41] - Management highlighted the importance of educating oncologists on the new survival data to drive adoption of LOQTORZI [38][39] Other Important Information - The company has reduced its headcount from approximately 228 at the end of 2024 to about 147 at the end of 2025, a reduction of about 35% [41] - Coherus is eligible for two earn-out sales milestones of $37.5 million each based on UDENYCA sales, which could provide additional financial support [43] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - In 2025, approximately 25% of business came from new patients, with the expectation that this mix will shift slightly more towards new patients in the future [51][53] Question: What is the promotional sensitivity of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [57] Question: What are the plans for exploring a triple combination with Tagmo? - The initial step will be to evaluate the combination of Tagmo and pasritamig before considering additional combinations [64] Question: How will data from ongoing trials be disclosed? - Data will be reported as it matures, either at congresses or through corporate disclosures, depending on the timing of patient accrual and scans [70] Question: What are the important updates on the competitive front for CCR8 this year? - The company anticipates more data disclosures from competitors, which could impact development strategies [80]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $61.8 million, a 31% increase compared to Q3 2025 [6][17] - Media margin reached $19.1 million, up 49% from Q3 2025 [6][17] - Adjusted EBITDA was approximately $0.2 million, an increase of $3.6 million from Q3 2025, representing 0.3% of Q4 revenue [7][21] - Full year 2025 revenue totaled $208.8 million, reflecting an 18% decline versus 2024 [8] - Adjusted EBITDA loss for the full year was $9 million, representing -4.3% of revenue [8][21] Business Line Data and Key Metrics Changes - Commerce Media Solutions contributed 56% of total Q4 revenue, more than doubling from 26% in Q4 2024 [4][8] - Commerce Media Solutions revenue for Q4 2025 was $34.7 million, representing 101% growth compared to Q4 2024 [17] - For the full year, Commerce Media Solutions revenue totaled $82.3 million, a 99% increase over 2024 [18] Market Data and Key Metrics Changes - The U.S. commerce media market is projected to grow at a compounded average growth rate of 21% from 2023 to 2027, reaching a total market value of $100 billion by 2027 [10] - As of year-end 2025, Commerce Media Solutions is operating at an annual run rate of $105 million [10] Company Strategy and Development Direction - The company has pivoted towards the high-growth commerce media industry, leveraging its owned and operated marketplaces [4] - The focus is on expanding Commerce Media Solutions and investing in strategic adjacencies to enhance brand differentiation and industry leadership [11][12] - The company aims to maintain a profitable contribution from its owned and operated business while using it as a test and learn engine for commerce media strategy [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth in 2026, supported by the growth of Commerce Media Solutions [23][27] - The company anticipates a return to year-over-year revenue growth, ending a multi-year period of managed decline [26] - Management highlighted the importance of maintaining financial flexibility and liquidity to support growth initiatives [25] Other Important Information - The company raised over $19 million in equity capital during 2025 to support growth investments [24] - A new financing agreement was entered into, providing expanded borrowing availability and improved financial flexibility [24] Q&A Session Summary Question: Can you discuss the AI-based functionality in your Rebuy partnership? - Management indicated that AI has been embedded in their solutions for improved performance, leveraging proprietary first-party data [31][32] Question: Can you elaborate on the convergence between owned and operated and Commerce Media capabilities? - Management emphasized the competitive advantage gained from extensive consumer data and the ability to drive unique audience sets [35][36] Question: What are your expectations for 2026 regarding Commerce Media growth? - Management expects strong double-digit growth for Commerce Media, with a range of greater than 50% and lower than 100% [66] Question: How is the macro environment impacting advertiser acquisition? - Management noted no significant pushback on pricing from advertisers, despite changes in return on ad spend [45][47] Question: What is the outlook for gross margins moving forward? - Management anticipates gross margins to expand into the mid-20s% by the latter half of 2026 [56] Question: How do you view the competitive landscape in the commerce media space? - Management acknowledged limited competition at the enterprise level, with a focus on building a competitive moat through direct partnerships [57][58]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled $8.6 million, a 36% increase compared to $6.3 million in Q4 2024 [29] - Full year revenue for 2025 was $32.4 million, up from $26.9 million in 2024 [29] - Gross margin for Q4 2025 was approximately 50%, while the full year gross margin was about 53% [30] - Operating loss for Q4 2025 was $5.6 million, compared to $7.6 million in Q4 2024 [31] - Adjusted operating loss for the full year 2025 was $9.3 million, improved from $12.4 million in 2024 [32] Business Line Data and Key Metrics Changes - System revenue for Q4 2025 was $3.3 million, reflecting partial revenue recognition on two Genesis systems [29] - Recurring revenue for Q4 2025 was $5.3 million, down from $9.4 million in Q4 2024, impacted by initial sales of new catheters [29] - Full year system revenue was $10.2 million, compared to $8.6 million in the prior year [29] - Full year recurring revenue was $22.2 million, up from $18.3 million in 2024, driven by increased catheter revenue [30] Market Data and Key Metrics Changes - The electrophysiology (EP) market is projected to grow from over $13 billion annually to $20 billion by 2030 [11] - The company views the market opportunity for robotics in EP as a $2 billion opportunity [12] Company Strategy and Development Direction - The company aims to pioneer robotics in minimally invasive endovascular surgery, focusing on making its robot widely available without requiring significant construction [9] - The strategy includes building an ecosystem of catheters, leveraging core technology for broader endovascular surgery applications, and establishing a digital backbone for connectivity [10] - Regulatory approvals for the GenesisX robot and associated catheters were achieved, marking a significant milestone [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming manufacturing challenges and anticipates significant commercial and strategic value creation in 2026 [19] - The company expects to deliver double-digit revenue growth in 2026, with quarterly revenue projected to ramp above $10 million in the latter half of the year [34] - Management highlighted the importance of establishing GenesisX programs and ramping catheter manufacturing to support revenue growth [19][21] Other Important Information - The company generated $4 million from a registered direct financing and $3.1 million from an at-the-market offering [33] - Cash and cash equivalents as of December 31, 2025, were $13.4 million with no debt [33] Q&A Session Summary Question: What is the goal for GenesisX programs and the mix of sales? - Management expects Genesis sales to continue at a similar pace as previous years, with mid-single digit numbers of Genesis systems sold annually [38] Question: What is included in the $3 million revenue goal for Synchrony in 2026? - The revenue guidance focuses on capital sales of Synchrony systems, with expectations for several hospitals to standardize their EP labs on Synchrony [41] Question: How is the allocation of MAGiC catheters being managed amid manufacturing constraints? - Management acknowledged the challenge of ramping manufacturing and is working closely with physicians to manage expectations and supply [46] Question: What are the economic models for GenesisX placements? - There are three core models: outright capital sale, lease, and placement with disposable commitments, with a mix expected in deals [71] Question: What is the outlook for operating expenses in 2026? - Management expects operating expenses to remain stable year-over-year, with adjustments based on project milestones and investments in manufacturing and commercial activities [80]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [9][25] - Fourth quarter revenue was $11.4 million, the highest quarterly revenue of the year, up 13% sequentially but down slightly year-over-year [25][9] - Gross margin for the fourth quarter was 68.6%, down from 71.4% year-over-year but up from 63.8% in the previous quarter [34][25] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [36][37] - Net loss for the fourth quarter was $3.8 million, or $0.09 per share, compared to a net loss of $300,000 or $0.01 per share for the same quarter last year [37][25] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved record quarterly revenue of over $1 million, up 81% year-over-year [32][11] - International revenue reached a record $2.2 million, up 46% year-over-year, primarily driven by growth in Germany [32][15] - The number of MyoPro units ordered in the fourth quarter was 241, up 5% sequentially [9][10] - Recurring patient sources represented 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [13][32] Market Data and Key Metrics Changes - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a multi-state agreement with Elevance Health covering 45 million lives [19][18] - The patient pipeline stood at 1,528 patients, an increase of 10% year-over-year [33][25] - The company faced challenges with Medicare Advantage payers, resulting in a decrease in authorizations and revenue from this segment [28][29] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [7][9] - A focus on managing cost structure and enhancing manufacturing processes to demonstrate operating leverage as the company scales [8][21] - Continued innovation in product development, including the launch of the MyoPro 2X and plans for the MyoPro 3 [46][39] - The strategic pivot towards recurring patient sources is expected to reduce customer acquisition costs and improve operating leverage [23][45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the O&P channel and international markets [90][91] - The company anticipates a challenging environment with Medicare Advantage payers but is working to secure more payer contracts [29][62] - For 2026, the company expects revenue in the range of $43 million to $46 million, with a focus on recurring sources [43][45] - Management aims to reduce cash burn by approximately 50% in 2026 compared to 2025 [45][41] Other Important Information - The company is investing in R&D, including a randomized controlled trial to support the efficacy of MyoPro [23][104] - The MyoConnect program has generated over 100 qualified candidates in its first six months, contributing to the patient pipeline [12][11] - The company plans to activate the Myomo mobile app for patients and clinicians, which is expected to reduce costs [21][23] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the fourth quarter? - Management noted that higher advertising costs in the fourth quarter were due to competition with holiday advertising and election cycles [55] Question: Can you provide details on the O&P channel's performance? - The company reported over $1 million in revenue from the O&P channel, with approximately 36 units ordered in the fourth quarter [60] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth in the O&P channel and international markets is expected to drive overall growth, while direct billing is anticipated to remain flat [61] Question: What is the current status of the pipeline ads and dropout rates? - The pipeline ads were lower due to a shutdown in the last days of 2025, and the dropout rate was affected by challenges in obtaining authorizations from Medicare Advantage [66][70] Question: How does the company plan to use data from the randomized controlled trial? - The data will be used to convince payers of the MyoPro's medical necessity and to support reimbursement efforts [104] Question: What is the expected gross margin for international operations compared to domestic? - International gross margins are expected to be slightly lower than domestic margins, but both will benefit from increased volume [110]

Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [21][22] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an increase of 570 basis points from the prior year [19][20] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli [20] - Adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [22] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8][19] - Women's health is a significant focus, with investments in launching this offering, including the acquisition of Optimal Human Health [5][6] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and receives more than 120,000 unique daily visitors to its websites, indicating strong brand demand [3] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15] Company Strategy and Development Direction - LifeMD aims to leverage its pharmacy infrastructure as a growth driver, with plans to enhance margins and deepen patient engagement [10][14] - The company is focusing on artificial intelligence to improve care delivery and operational efficiency, with plans to launch an AI clinical decision support tool [11][12] - LifeMD is committed to building a comprehensive virtual women's healthcare offering, addressing significant unmet demand in the market [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [17] - The company anticipates returning to Adjusted EBITDA profitability in Q2 2026, driven by investments in patient acquisition [23] - Management highlighted the importance of insurance enablement in improving customer acquisition costs and retention [15][16] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, providing financial flexibility for growth investments [3][22] - The company is exploring partnerships with large pharmaceutical companies to expand its offerings and enhance its market position [5] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [27] Question: Revenue model for Wegovy pill - The Wegovy pill is typically priced at $249 per month, with healthy gross margins around $100 per order [30] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, expecting to drive patient acquisition while reducing customer acquisition costs [33] Question: Revenue ramp drivers for 2026 - Key drivers include subscriber count growth in the GLP-1 weight business, growth in women's health, and continued performance in men's health [36] Question: Stickiness of Wegovy pill versus injectable - Initial retention rates for the Wegovy pill are better than the injectable, but long-term retention is still to be determined [54] Question: Comparison with competitors - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering various specialty services [56][57] Question: Patient acquisition channels - The marketing strategy remains similar, with new partnerships delivering strong performance in patient acquisition [62] Question: Lifetime value of covered patients versus cash pay patients - Management believes that patients using insurance will have better retention and lifetime value compared to cash pay patients, though this needs further validation [64][67] Question: Subscriber count and demand for Wegovy - LifeMD has 322,000 overall subscribers, with strong demand for the Wegovy pill driving new patient acquisition [71] Question: In-house fulfillment percentage and margin lift - Approximately 70% of fulfillment is handled in-house, with an estimated margin improvement of 150-200 basis points [72]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled $8.6 million, a 36% increase from $6.3 million in Q4 2024 [30] - Full year 2025 revenue was $32.4 million compared to $26.9 million in 2024 [30] - Gross margin for Q4 and full year 2025 was approximately 50% and 53% respectively [31] - Operating loss for Q4 2025 was $5.6 million, improved from $7.6 million in Q4 2024 [32] - Negative free cash flow for the full year was $13.8 million, compared to $8.5 million in 2024 [33] Business Line Data and Key Metrics Changes - System revenue for Q4 was $3.3 million, up from $1.4 million in the prior year [30] - Recurring revenue for Q4 was $5.3 million, down from $9.4 million in the prior year [30] - Full year system revenue was $10.2 million compared to $8.6 million in the prior year [30] - Full year recurring revenue was $22.2 million, up from $18.3 million in the prior year [31] Market Data and Key Metrics Changes - The electrophysiology (EP) market is projected to grow from over $13 billion to $20 billion by 2030 [14] - The company views the market opportunity for robotics in EP as $2 billion [15] Company Strategy and Development Direction - The company aims to pioneer robotics in minimally invasive endovascular surgery, focusing on making its robot widely available and building an ecosystem of catheters [10][11] - Key strategic pillars include rapid installation of robots, reducing dependencies on third-party catheters, leveraging core technology for broader applications, and establishing a digital backbone for connectivity [10][11] - The company achieved regulatory approvals for the GenesisX robot and associated catheters, marking a significant milestone [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth in 2026, with expectations for quarterly revenue to ramp above $10 million in the latter half of the year [35] - The company anticipates a working capital benefit to cash flow in 2026 after significant investments in working capital in 2025 [36] - Management is optimistic about overcoming manufacturing challenges and expects to establish a strong foundation for future growth [29] Other Important Information - The company has a cash balance of $13.4 million and no debt as of December 31 [34] - Manufacturing challenges have been a focus, particularly with the MAGiC catheter, which faced production issues [22][74] Q&A Session Summary Question: What is the goal for GenesisX programs and sales expectations? - Management expects Genesis sales to continue at a similar pace as previous years, with mid-single digit numbers of Genesis systems sold annually [39] Question: What is the revenue goal for Synchrony in 2026? - The revenue goal includes capital sales and recurring revenue from service contracts and software subscriptions, with several hospitals expected to standardize their EP labs on Synchrony [43] Question: How is the allocation of MAGiC catheters being managed amid manufacturing constraints? - Management acknowledged the challenge of ramping manufacturing and is working to ensure that administrative efforts are in place to meet demand as production increases [49] Question: What are the economic models for GenesisX? - Three core models are being utilized: outright capital sale, leasing, and placement with disposable commitments, allowing flexibility in revenue generation [76] Question: What is the outlook for the Chinese market? - The company expects the first Genesis systems to be sold in China this year, with ongoing efforts to transition to new catheter systems and regulatory submissions [90]

Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [21][22] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an increase of 570 basis points from the prior year [19][20] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli [20] - Adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [20] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8] - Women's health is a significant focus, with investments in launching this offering, including acquiring Optimal Human Health MD and partnerships with recognized experts in the field [5][6][7] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and receives more than 120,000 unique daily visitors to its websites, indicating strong brand strength and demand for services [3] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15] Company Strategy and Development Direction - LifeMD is focused on leveraging artificial intelligence to enhance care delivery, diagnostics, and patient operations, with plans to launch an AI clinical decision support tool in the first half of 2026 [11][12] - The company aims to build a comprehensive technology platform that integrates emerging AI capabilities and insurance benefits to improve patient experience [15][16] - LifeMD is committed to expanding its pharmacy operations, which are now licensed in all 50 states, to support personalized compounded medications [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [17] - The company anticipates returning to adjusted EBITDA profitability in Q2 2026 after making significant investments in patient acquisition [23] - Management highlighted the importance of insurance enablement in driving customer acquisition and retention, with expectations of improved metrics in this area [15][64] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, providing financial flexibility for growth investments [3][22] - The company is seeing high demand for the oral Wegovy pill, which has significantly contributed to new patient acquisitions in the weight management segment [27][71] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [27] Question: Revenue model for Wegovy pill - The pricing for the Wegovy pill is typically around $249 per month, with healthy gross margins of approximately $100 per order [30] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, with a focus on driving patient acquisition while reducing customer acquisition costs [33] Question: Revenue ramp and drivers - Growth will primarily come from subscriber count increases in the GLP-1 weight management business, women's health, and the Rex MD brand [36] Question: Women's health performance compared to other markets - Initial performance in women's health shows high intent and promising retention rates, with significant investments made in marketing and advisor partnerships [43][45] Question: Stickiness of Wegovy pill versus injectable - Retention rates for the Wegovy pill are better than the injectable, but long-term retention is still to be determined [54] Question: Comparison with competitors - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering synchronous care and a range of specialty services [56][58] Question: Patient acquisition channels - The marketing strategy remains similar to past efforts, with new partnerships yielding strong performance in patient acquisition [62] Question: Lifetime value of covered patients versus cash pay patients - Management believes that patients using insurance will have better retention and lifetime value compared to cash pay patients, though this is still being validated [64][67] Question: In-house pharmacy fulfillment - Approximately 70% of fulfillment is handled in-house, leading to a margin improvement of 150-200 basis points [72]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $40.9 million, representing a 26% growth over 2024 [5][21] - Fourth quarter revenue was $11.4 million, the highest revenue quarter of the year, up 13% from the third quarter but down slightly year-over-year [14][19] - Gross margin for the fourth quarter was 68.6%, down from 71.4% a year ago, but up from 63.8% in the third quarter [19] - Operating loss for the fourth quarter was $2.8 million, compared to an operating loss of about $200,000 in the prior year quarter [20] Business Line Data and Key Metrics Changes - The U.S. Orthotics and Prosthetics (O&P) channel achieved quarterly revenue exceeding $1 million for the first time, up 81% year-over-year [6][18] - Revenue from the O&P channel was up 81% for the quarter and doubled for the year [6][8] - The MyoConnect program contributed to 42% of fourth quarter revenue, up from 26% in the fourth quarter of 2024 [8] Market Data and Key Metrics Changes - International operations delivered quarterly revenues exceeding $2 million for the first time, growing 46% for the quarter and 48% for the year [8][18] - The company signed in-network contracts with additional Medicare Advantage and commercial payers, including a significant agreement with Elevance Health covering 45 million lives [10] Company Strategy and Development Direction - The company aims to grow revenue through direct-to-patient marketing and expand orders from recurring sources [4] - A focus on managing cost structure and enhancing manufacturing processes to demonstrate operating leverage as the company scales [4] - Continued innovation in product development to maintain market leadership, including the launch of the MyoPro 2X and development of MyoPro 3 [12][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth in recurring patient sources and the MyoConnect program, which is expected to reduce customer acquisition costs [8][28] - The company anticipates a revenue range of $43 million to $46 million for 2026, with a focus on stroke patients and recurring sources [24][25] - Management acknowledged challenges with Medicare Advantage payers but is encouraged by new payer contracts leading to more authorizations [17][41] Other Important Information - The company plans to activate the Myomo mobile app for patients and clinicians, which is expected to reduce costs associated with shipping laptops [12] - Cash burn was reported at $1.5 million in the fourth quarter, with operating cash flow negative at $1.1 million [22] Q&A Session Summary Question: What drove the increase in cost per pipeline ad in the MyoConnect program? - Management noted that the fourth quarter typically has higher advertising costs due to competition and has implemented changes to reduce costs moving forward [34][35] Question: Can you provide details on the O&P channel's performance? - The O&P channel had over $1 million in revenue with approximately 36 units ordered in the fourth quarter [39] Question: What are the assumptions for the U.S. O&P business in 2026 guidance? - Growth is expected in the O&P channel and international markets, while direct billing is anticipated to remain flat [40][41] Question: What is the current status of the pipeline and dropout rates? - The pipeline added 676 patients, slightly lower than previous quarters, with a dropout rate around 20% due to challenges with Medicare Advantage authorizations [45][56] Question: What is the expected gross margin for the upcoming quarters? - Management expects first quarter gross margin to be lower than the fourth quarter but aims to improve gross margin to the 70% range by the end of 2026 [59][61]

Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [22][23] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an expansion of 570 basis points from the prior year [20][21] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli, while the adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [21][24] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8][19] - Women's health is a significant focus, with investments in launching this offering, including the acquisition of Optimal Human Health MD and partnerships with recognized experts in the field [5][6] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and is onboarding approximately 1,200 new patients daily, reflecting strong brand demand [3][19] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15][16] Company Strategy and Development Direction - LifeMD is focused on leveraging artificial intelligence to enhance care delivery, diagnostics, and patient operations, with plans to launch an AI clinical decision support tool in the first half of 2026 [11][12] - The company aims to build a comprehensive virtual healthcare platform that integrates emerging AI capabilities and insurance benefits, enhancing patient experience and operational efficiency [16][17] - LifeMD is committed to expanding its pharmacy operations, which are now licensed in all 50 states, to support personalized compounded medications and improve margins [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [18] - The company anticipates returning to adjusted EBITDA profitability in Q2 2026, with revenue guidance for 2026 projected between $220 million and $230 million [25] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, allowing for aggressive investment in growth initiatives [3][24] - The company is seeing significant pipeline opportunities with large pharmaceutical companies, enhancing its attractiveness as a partner in the healthcare space [5] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [29] Question: Revenue model for Wegovy pill - The Wegovy pill is typically priced at $249 per month, with healthy gross margins around $100 per order [31] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, expecting to drive patient acquisition and revenue growth [34] Question: Drivers of revenue increase in 2026 - Growth will primarily come from subscriber count increases in the GLP-1 weight management business, women's health, and the Rex MD brand [37] Question: Women's health performance compared to other markets - Early performance in women's health shows higher intent and promising retention rates, with significant investments made in marketing and brand development [44][46] Question: Stickiness of Wegovy pill versus injectable - Initial retention rates for the Wegovy pill are better than the injectable, but long-term retention remains to be seen [54] Question: Comparison with competitors like Amazon - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering synchronous care and a range of specialty services [56][58]